Cite
APA Citation
Tewari, K. S., Vergote, I., Oaknin, A., Alvarez, E., Gaillard, S., Lheureux, S., Rischin, D., Santin, A. D., Feng, M., Mathias, M., Fury, M., Lowy, I., & Monk, B. J. (n.d.). 280TiPGOG 3016/ENGOT-cx9: An open-label, multi-national, randomized, phase III trial of cemiplimab, an anti-PD-1, versus investigator's choice (IC) chemotherapy in ≥ second-line recurrent or metastatic cervical cancer. Annals of oncology, 29, . http://access.bl.uk/ark:/81055/vdc_100095322448.0x000038